Bioglutide (NA-931): Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •5 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
Bioglutide (NA-931) is not FDA-approved for any indication. It has only completed Phase 1 and Phase 2 trials with limited participants (n=74 and n=125) and short durations (28 days and 13 weeks). The safety profile is incompletely characterized.
No data beyond 13 weeks of treatment exist. Chronic use safety, including effects on cancer risk (IGF-1R agonism), hepatic function (glucagon agonism), and cardiovascular outcomes, is unknown.
Chronic activation of the IGF-1 receptor has theoretical associations with cell proliferation and cancer risk. The long-term implications of sustained pharmacological IGF-1R agonism in an anti-obesity agent are unknown and require careful monitoring in Phase 3 and post-marketing studies.
Glucagon receptor activation stimulates hepatic glucose output, which could theoretically worsen glycemic control in patients with type 2 diabetes. Effects on liver function with chronic GCGR activation are unknown.
Biomed Industries, Inc. is a small pharmaceutical company with limited resources compared to major developers (Novo Nordisk, Eli Lilly). Drug development delays, insufficient funding for Phase 3 trials, or failure to reach commercialization are inherent risks.
⚠️Important Warnings
- •INVESTIGATIONAL DRUG: Bioglutide (NA-931) is not approved by the FDA or any other regulatory authority for any indication. It is available only through clinical trial participation.
- •LIMITED SAFETY DATA: Only approximately 199 subjects have been exposed to NA-931 in clinical trials, with a maximum treatment duration of 13 weeks. This is insufficient to detect rare or delayed adverse effects.
- •NO LONG-TERM DATA: The chronic use safety profile of Bioglutide is unknown. Risks associated with prolonged IGF-1 receptor agonism, glucagon receptor agonism, or combined multi-receptor activation have not been evaluated.
- •NOT FOR SELF-ADMINISTRATION: Bioglutide should not be obtained, purchased, or used outside of approved clinical trials. Any product claiming to be NA-931 or Bioglutide sold through non-clinical-trial channels is unauthorized and potentially dangerous.
- •PREGNANCY: No reproductive toxicology data are available. Bioglutide should not be used during pregnancy or by women planning to become pregnant.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Not FDA-approved. Active IND with Phase 2 completed and Phase 3 planned. Available only through clinical trial enrollment. Not legally available for prescription, purchase, or use outside of clinical trials. |
| European Union | Investigational | Not approved by EMA. Phase 2 data were presented at EASD 2025 (Vienna) but no regulatory submission has been made. Not available for prescription or purchase. |
| International | Investigational | Not approved by any regulatory authority worldwide. Available only through clinical trial enrollment at designated study sites. Any sale or distribution outside of clinical trials would be unauthorized. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
0View community protocolsCritical Safety Information#
Bioglutide (NA-931) is an investigational drug that has not been approved by the FDA, EMA, or any other regulatory authority for any indication. All information below is derived from early-stage clinical trial data (Phase 1 and Phase 2) with limited sample sizes and short treatment durations. The full risk profile of Bioglutide is not established.
Investigational Drug Risk#
The most fundamental risk associated with Bioglutide is its investigational status. The drug has been evaluated in only two clinical trials enrolling a combined total of approximately 199 subjects, with maximum treatment duration of 13 weeks. For context:
- Semaglutide's clinical program enrolled over 25,000 participants across 20+ trials with up to 3+ years of follow-up before and after approval
- Tirzepatide's SURMOUNT program enrolled over 5,000 participants for weight management
- Many promising early-stage drugs fail in Phase 3 trials or during regulatory review
Phase 2 data, while encouraging, are insufficient to establish a drug's safety and efficacy profile. Approximately 30-40% of drugs that complete Phase 2 fail to demonstrate acceptable safety or efficacy in Phase 3 trials.
Mechanism-Specific Risks#
IGF-1 Receptor Agonism#
Bioglutide is the first anti-obesity agent to include IGF-1 receptor agonism. While this mechanism is credited with the observed muscle mass preservation, chronic IGF-1R activation raises several theoretical concerns:
- Proliferative signaling: The IGF-1 signaling pathway promotes cell growth and inhibits apoptosis. Elevated endogenous IGF-1 levels have been epidemiologically associated with increased risk of certain cancers (breast, prostate, colorectal), though the relationship is complex and context-dependent
- Unknown duration effects: No clinical or epidemiologic data exist on the long-term effects of chronic pharmacological IGF-1R agonism from an oral small molecule
- Dose-response uncertainty: The degree of IGF-1R activation produced by Bioglutide at therapeutic doses has not been publicly characterized
These concerns do not indicate that Bioglutide causes cancer -- they reflect theoretical risks that require monitoring in long-term studies. Many endogenous physiological processes involve IGF-1R signaling, and the degree and pattern of activation matters.
Glucagon Receptor Agonism#
Glucagon receptor activation is a dual-edged mechanism:
- Beneficial effects: Promotes hepatic lipid oxidation, energy expenditure, and thermogenesis, contributing to weight loss
- Potential risks: Stimulates hepatic glucose output, which could worsen glycemic control in patients with type 2 diabetes; could affect liver function with chronic activation; hyperglucagonemia has been associated with hepatic steatosis in some contexts
Similar glucagon receptor agonism is present in retatrutide and survodutide, which are also under clinical investigation. The safety of chronic GCGR activation remains an active area of research.
GLP-1 Receptor Agonism (Class Risks)#
Based on the established GLP-1 agonist class, potential risks include:
- Pancreatitis: Rare but reported with all GLP-1 agonists. Not reported in Bioglutide trials, but sample sizes were insufficient for detection.
- Gallbladder disease: Associated with rapid weight loss. The 13.8% weight loss at 13 weeks represents rapid weight reduction; cholelithiasis risk may emerge with longer treatment.
- Thyroid C-cell tumors: Rodent class effect leading to boxed warnings for all peptide GLP-1 agonists. Whether this applies to a small-molecule agonist with potentially different receptor binding kinetics is unknown.
- Gastroparesis and ileus: Rare complications of delayed gastric emptying with GLP-1 agonists. Bioglutide's effect on gastric emptying has not been characterized.
Regulatory and Legal Status#
Current Status#
Bioglutide is an investigational new drug (IND) in the United States. It is not approved by any regulatory authority worldwide.
| Jurisdiction | Status | Availability |
|---|---|---|
| United States (FDA) | Investigational (Phase 2 complete) | Clinical trial sites only |
| European Union (EMA) | Not submitted | Not available |
| United Kingdom (MHRA) | Not submitted | Not available |
| Canada (Health Canada) | Not submitted | Not available |
| Australia (TGA) | Not submitted | Not available |
Projected Timeline#
Based on the announced Phase 3 plans and typical drug development timelines, FDA approval, if achieved, would likely be several years away (earliest 2028-2029, assuming Phase 3 success). This timeline is speculative and subject to numerous uncertainties.
Legal Considerations#
- Bioglutide is available only through clinical trial enrollment at approved study sites
- Any sale, distribution, or promotion of NA-931/Bioglutide outside of clinical trials is unauthorized
- Products marketed as NA-931 or Bioglutide through online retailers, peptide suppliers, or compounding pharmacies are not legitimate clinical trial material
- Research-use-only chemicals claiming to be NA-931 have not been validated for identity, purity, or safety
At-Risk Populations#
Patients with Cancer History#
Given the theoretical concerns about IGF-1R agonism and cell proliferation, patients with active malignancies or a recent history of cancer should exercise particular caution. Clinical trials may exclude such patients.
Patients with Type 2 Diabetes#
The combination of glucagon receptor agonism (which raises blood glucose) and GLP-1/GIP agonism (which lowers it) creates a complex glycemic dynamic. The net effect in diabetic patients has not been specifically characterized, though Phase 1 included some patients with type 2 diabetes.
Pregnant and Breastfeeding Women#
No reproductive toxicology data are available for Bioglutide. The drug should not be used during pregnancy or by women planning to become pregnant. It is unknown whether Bioglutide is excreted in breast milk.
Hepatically or Renally Impaired Patients#
No data exist in patients with hepatic or renal impairment. Given the glucagon receptor's hepatic effects, liver function monitoring may be particularly relevant.
Risk-Benefit Context#
The potential benefits of Bioglutide (significant weight loss, oral administration, muscle preservation, low GI side effects) are based on early-stage clinical data that have not yet been confirmed in Phase 3 trials. The potential risks (unknown long-term safety of multi-receptor agonism, small company development risk, uncharacterized drug interactions) are inherent to any investigational drug at this stage.
Patients interested in Bioglutide should consider enrollment in clinical trials through legitimate channels (clinicaltrials.gov: NCT06564753, NCT06732245) and should not attempt to obtain or use the drug outside of supervised clinical research.
Summary of Key Warnings#
- Not approved for any use by any regulatory authority
- Limited safety data from small, short trials
- Unknown long-term effects of quadruple receptor agonism
- Theoretical cancer risk from chronic IGF-1R activation (not demonstrated, monitoring needed)
- Unknown glycemic effects of combined glucagon and incretin agonism in diabetic patients
- No drug interaction data available
- No reproductive safety data available
- Not available outside of clinical trials -- do not obtain from unauthorized sources
Related Reading#
Frequently Asked Questions About Bioglutide (NA-931)
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.